Pulse Biosciences, Inc. (PLSE) - Stock Analysis
Last updated: Apr 6, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
High-impact AFib feasibility data and FDA IDE for NANOPULSE-AF, plus an upcoming Q4 call, have driven a ~66% 21-day surge and clear breakout; with minimal revenue and cash-burn risk this is a speculative but genuinely news-driven short-term hot momentum name.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong liquidity ⢠Persistent losses ⢠Severe valuation gap PLSE has a rock-solid balance sheet and runway (large cash, negligible debt, high current ratio) but is burning cash with deep recurring losses and an extreme market valuation disconnected from revenue â require rapid revenue growth or cost cuts to justify the price.
Price Behavior
Key Price Behavior Insights: ⢠Strong rebound ⢠Higher highs/lows ⢠Fast run risk Support Level: $21.0â$21.5 (secondary $18.1â$19.0) Resistance Level: $25.2â$25.5 PLSE is in a short-term uptrendâtrading $23.00 well above the last-month simple average (~$21.05) after a ~24% rally from earlyâMarch lows, though the rapid run and February volatility raise shortâterm retracement risk.
Sentiment & News
Key News Insights: ⢠Durable thyroid ⢠AFib pivot ⢠Early malignancy trial Pulse Biosciences is rapidly commercializing its nPulse PFA platform with durable benign thyroid results, malignant thyroid feasibility enrollments, and strong European AFib data prompting a strategic shift and accelerated investment in the cardiac catheter program.
AI Summary
PLSE has shifted from a pilot-stage device developer to a platform company concentrated on a potentially transformative nPulse cardiac ablation program, making its valuation now binary on successful pivotal EP funding, enrollment, and clinical outcomes rather than near-term revenue. Actionable: remain in a watch/validate posture until the company secures nonâdilutive or partnered pivotal funding and produces pivotal-ready, adjudicated safety/efficacy data (or until cashâburn guidance materially improves).
Description
Pulse Biosciences, Inc. is a bioelectric medicine company that develops the CellFX System, a console-based platform that delivers nanosecond electrical pulses (Nano-Pulse Stimulation) to non-thermally remove targeted cells while sparing surrounding non-cellular tissue. The company was incorporated in 2014, changed its name from Electroblate, Inc. to Pulse Biosciences in December 2015, and is headquartered in Hayward, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Feb 18 | Feb 25 | PLSE | Pulse Biosciences, Inc. | High-impact AFib feasibility data and FDA IDE for NANOPULSE-AF, plus an upcoming Q4 call, have driven a ~66% 21-day surge and clear breakout; with minimal revenue and cash-burn risk this is a speculative but genuinely news-driven short-term hot momentum name. | Closed | -24.6% |
| Feb 11 | Feb 18 | PLSE | Pulse Biosciences, Inc. | FDA IDEs for NANOPULSEâAF and nPulse 360 EP plus strong firstâinâhuman ablation data (150 patients, presented 2026â02â05) triggered a ~75% threeâday jump and price ~55% above its 21âday SMA, making PLSE a highâvolatility clinicalâcatalyst momentum trade into the 2026â02â19 earnings update. | Closed | +0.8% |